As of Nov 19, 2026, 2 of 2 active firms rate ABOS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ABOS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.32 – $-0.25 · 2 analysts · -14% YoY
Next period, 2 analysts expect Acumen Pharmaceuticals Inc to earn $-0.28 a share (range $-0.32 – $-0.25), versus $-0.33 a year earlier. Full-year consensus is $-1.61, growing to $-0.49 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Acumen Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABOS.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$11.00+5555.5% to target
Overall win rate
45%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Sell
No targeton ABOS
Overall win rate
35%
+ Follow
#3
Thomas Shrader
BTIG · Rank #553
Buy
$8.00+4013.1% to target
Overall win rate
32%
+ Follow
#4
Paul Matteis
Stifel
Neutral
$1.00+414.1% to target
Coverage
—
+ Follow
#5
Geoff Meacham
Citigroup
Buy
$5.00+2470.7% to target
Coverage
—
+ Follow
ABOS stock forecast FAQ
What is ABOS's average 12-month price target?+
The 2 active firms with a live target average $6.50 for Acumen Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $5.00 low, as of Nov 19, 2026.
Is ABOS stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ABOS?+
The Street-high target is $8.00 (BTIG), and the Street-low is $5.00 (Citigroup). The average of all 2 active-firm targets is $6.50.
How many active Wall Street firms cover ABOS?+
2 active firms have a recognized rating on Acumen Pharmaceuticals Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ABOS?+
Among analysts who currently cover ABOS, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $11.00 target.
What is Acumen Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.32 – $-0.25) across 2 analysts. Full-year EPS is projected at $-1.61, rising to $-0.49 the following year.
How much revenue is Acumen Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ABOS lately?+
As of Nov 19, 2026, 2 of 2 active firms rate ABOS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABOS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.